The big approvals still on the cards for 2021

Biogen got a win last week with US approval of its Alzheimer’s drug Aduhelm, but there are plenty of other developers still waiting for regulatory decisions. In fact, a look back at Evaluate Vantage’s preview of the year’s 10 potential biggest launches, written in January, shows that, almost half way through 2021, only three have received a green light.